158 related articles for article (PubMed ID: 24461289)
21. Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.
Nettekoven M; Fingerle J; Grether U; Grüner S; Kimbara A; Püllmann B; Rogers-Evans M; Röver S; Schuler F; Schulz-Gasch T; Ullmer C
Bioorg Med Chem Lett; 2013 Mar; 23(5):1177-81. PubMed ID: 23380378
[TBL] [Abstract][Full Text] [Related]
22. Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches.
Hickey ER; Zindell R; Cirillo PF; Wu L; Ermann M; Berry AK; Thomson DS; Albrecht C; Gemkow MJ; Riether D
Bioorg Med Chem Lett; 2015 Feb; 25(3):575-80. PubMed ID: 25556098
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, biological evaluation and binding mode modeling of benzimidazole derivatives targeting the cannabinoid receptor type 1.
Espinosa-Bustos C; Lagos CF; Romero-Parra J; Zárate AM; Mella-Raipán J; Pessoa-Mahana H; Recabarren-Gajardo G; Iturriaga-Vásquez P; Tapia RA; Pessoa-Mahana CD
Arch Pharm (Weinheim); 2015 Feb; 348(2):81-8. PubMed ID: 25641513
[TBL] [Abstract][Full Text] [Related]
24. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
[TBL] [Abstract][Full Text] [Related]
25. Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist.
Sime M; Allan AC; Chapman P; Fieldhouse C; Giblin GM; Healy MP; Lambert MH; Leesnitzer LM; Lewis A; Merrihew RV; Rutter RA; Sasse R; Shearer BG; Willson TM; Xu RX; Virley DJ
Bioorg Med Chem Lett; 2011 Sep; 21(18):5568-72. PubMed ID: 21798739
[TBL] [Abstract][Full Text] [Related]
26. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
[TBL] [Abstract][Full Text] [Related]
27. Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
Qian HY; Wang ZL; Xie XY; Pan YL; Li GJ; Xie X; Chen JZ
Eur J Med Chem; 2017 Sep; 137():598-611. PubMed ID: 28651225
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.
Kusakabe K; Tada Y; Iso Y; Sakagami M; Morioka Y; Chomei N; Shinonome S; Kawamoto K; Takenaka H; Yasui K; Hamana H; Hanasaki K
Bioorg Med Chem; 2013 Apr; 21(7):2045-55. PubMed ID: 23395112
[TBL] [Abstract][Full Text] [Related]
30. The therapeutic journey of benzimidazoles: a review.
Bansal Y; Silakari O
Bioorg Med Chem; 2012 Nov; 20(21):6208-36. PubMed ID: 23031649
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.
Pasquini S; Mugnaini C; Ligresti A; Tafi A; Brogi S; Falciani C; Pedani V; Pesco N; Guida F; Luongo L; Varani K; Borea PA; Maione S; Di Marzo V; Corelli F
J Med Chem; 2012 Jun; 55(11):5391-402. PubMed ID: 22548457
[TBL] [Abstract][Full Text] [Related]
33. Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
Cherney RJ; Mo R; Meyer DT; Pechulis AD; Guaciaro MA; Lo YC; Yang G; Miller PB; Scherle PA; Zhao Q; Cvijic ME; Barrish JC; Decicco CP; Carter PH
Bioorg Med Chem Lett; 2012 Oct; 22(19):6181-4. PubMed ID: 22939233
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of positional isomers of 5 and 6-bromo-1-[(phenyl)sulfonyl]-2-[(4-nitrophenoxy)methyl]-1H-benzimidazoles as possible antimicrobial and antitubercular agents.
Ranjith PK; Rajeesh P; Haridas KR; Susanta NK; Row TN; Rishikesan R; Kumari NS
Bioorg Med Chem Lett; 2013 Sep; 23(18):5228-34. PubMed ID: 23942420
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
[TBL] [Abstract][Full Text] [Related]
36. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
37. Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.
Manera C; Saccomanni G; Adinolfi B; Benetti V; Ligresti A; Cascio MG; Tuccinardi T; Lucchesi V; Martinelli A; Nieri P; Masini E; Di Marzo V; Ferrarini PL
J Med Chem; 2009 Jun; 52(12):3644-51. PubMed ID: 19435366
[TBL] [Abstract][Full Text] [Related]
38. Novel research strategies of benzimidazole derivatives: a review.
Barot KP; Nikolova S; Ivanov I; Ghate MD
Mini Rev Med Chem; 2013 Aug; 13(10):1421-47. PubMed ID: 23544603
[TBL] [Abstract][Full Text] [Related]
39. Morpholine containing CB2 selective agonists.
Zindell R; Riether D; Bosanac T; Berry A; Gemkow MJ; Ebneth A; Löbbe S; Raymond EL; Thome D; Shih DT; Thomson D
Bioorg Med Chem Lett; 2009 Mar; 19(6):1604-9. PubMed ID: 19243942
[TBL] [Abstract][Full Text] [Related]
40. New benzimidazoles as thrombopoietin receptor agonists.
Safonov IG; Heerding DA; Keenan RM; Price AT; Erickson-Miller CL; Hopson CB; Levin JL; Lord KA; Tapley PM
Bioorg Med Chem Lett; 2006 Mar; 16(5):1212-6. PubMed ID: 16376078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
